Literature DB >> 508461

Diazoxide in treatment of primary pulmonary hypertension.

J M Rubino, J S Schroeder.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508461      PMCID: PMC482163          DOI: 10.1136/hrt.42.3.362

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


× No keyword cloud information.
  3 in total

1.  Influence of intravenous injection rate on protein binding and vascular activity of diazoxide.

Authors:  E M Sellers; J Koch-Weser
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

2.  Primary pulmonary hypertension: a fatality during pulmonary angiography. Clinical conference from Boston University School of Medicine.

Authors: 
Journal:  Chest       Date:  1973-11       Impact factor: 9.410

3.  [Effect of diazoxide, a new bllood pressure lowering substance, on the general and pulmonary circulatory system in hypertension].

Authors:  H Just; U Stein
Journal:  Z Kreislaufforsch       Date:  1969-09
  3 in total
  6 in total

1.  Primary pulmonary hypertension.

Authors:  T Higenbottam
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

2.  Management of primary pulmonary hypertension.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1985-01

Review 3.  Drug treatment of primary pulmonary hypertension.

Authors:  A A McLeod; D E Jewitt
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

4.  Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.

Authors:  N S Chan; J McLay; A C Kenmure
Journal:  Br Heart J       Date:  1987-02

5.  Detrimental effects of verapamil in patients with primary pulmonary hypertension.

Authors:  M Packer; N Medina; M Yushak; I Wiener
Journal:  Br Heart J       Date:  1984-07

6.  Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Authors:  David Langleben; Stylianos Orfanos
Journal:  Pulm Circ       Date:  2017-06-20       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.